Do Pharma Mergers and Acquisitions Improve R&D Productivity and Increase Shareholder Value?

White Paper


Do Pharma Mergers And Acquisitions Improve R&D Productivity And Increase Shareholder Value?

Mergers & acquisitions (M&As) have long been used as a critical strategic instrument by pharmaceutical company executives to spur R&D innovation, sustain financial growth, and generate cost efficiencies.  The pharma industry has recently seen a flurry of significant M&As with more surely to follow. This white paper highlights the importance that M&As will have on the future performance of pharma companies. M&As will be required to achieve strategic objectives by augmenting and/or complementing existing company R&D pipelines as the risks and costs of developing new innovative medicines increase over time. The challenges for pharma companies are making the right targeting decisions for M&As and tactically ensuring such deals achieve strategic goals.

The objectives of this white paper are designed to help pharma executives in making critical M&A decisions by addressing five key questions:

  1. What is (will be) driving current and future M&A deals?
  2. Do M&As improve R&D productivity? If so, how? If not, why not?
  3. Do M&As increase shareholder value? If so, how? If not, why not?
  4. Are there any therapy classes that are more likely targets for increased M&A activity?
  5. What kinds of analyses should companies conduct when considering M&As in order to increase the probability of such deals improving R&D productivity and increasing shareholder value?


Complete the brief form to download the white paper.

Contact us at with any questions.

Get Your Copy!

Suggested Blogs

Let Us Show You What Axtria’s 

Solutions Can Do For You